Abstract
Olanzapine is a new antipsychotic agent with serotonin/dopamine antagonism action. Efficacy in treating overall psychopathology in acute schizophrenia as measured by the BPRS0-6 total score was demonstrated at 10 mg/day versus placebo; at doses in a 5-20 mg/day range, olanzapine was comparable or superior to haloperidol. Superior efficacy for negative and depressive symptoms was shown in comparison to haloperidol. Olanzapine has a favorable acute and tardive extrapyramidal symptom profile relative to haloperidol and caused substantially less elevation of serum prolactin. Dose- related weight gain and asymptomatic mild transaminase elevations occurred in olanzapine-treated patients.
Original language | English (US) |
---|---|
Pages (from-to) | 45-49 |
Number of pages | 5 |
Journal | Journal of Clinical Psychiatry |
Volume | 58 |
Issue number | SUPPL. 10 |
State | Published - Aug 20 1997 |
Externally published | Yes |
ASJC Scopus subject areas
- Psychiatry and Mental health